anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an access management system to prevent spread of infectious diseases using hybrid location information. A management server (11) is connected to a store server (12) and a plurality of user terminals (13) through a network. The management server (11) includes a store DB (22) and a reference DB (25) including store information. The store DB (22) stores visitor information and access time of a store, and the reference DB (25) stores pre-measured data to determine an indoor location for each store. When a pre-designated and pre-equipped identification number is recognized by the user terminals (13), the user terminals (13) transmit the recognized identification number and user information to the management server (11). An access confirmation module (36) recognizes the user and the store, lists them in visitor DB (23), and transmits a check-in message to the user terminal. A location identification module (31) transmits data for indoor location identification stored in the reference DB (25) to the user terminal, and compares the data for indoor location identification sent from the user terminal with the information in the reference DB (25) so that the store that is identified is correct. If an indoor location identification module (32) of the user terminal (13) does not identify that the user is indoors, it is regarded as checked out and the management server (11) updates the visitor DB (23) to provide information of the user entering and leaving the store for allowing it manageable.
NEW MATERIAL:The compound of formula I [R<1> and R<2> are H, (substituted) lower alkyl or lower alkenyl, (substituted)alicyclic group, aryl or heterocyclic group; R<3> is lower alkyl]. EXAMPLE:3-Cyano-N,N-dibenzyl-2-methylthio-4H-quinolizin-4-one-1-carbox amide. USE:Medicine. It has an activity to suppress the formation of antibody of immunoglobulin E (IgE) and is useful as a remedy for diseases caused by IgE, e.g. bronchial asthma, rhinitis, dermatitis, anaphylaxis, etc. PREPARATION:The compound of formula I can be produced by reacting 2- pyridylacetic acid with an amine derivative of formula II by conventional method, thermally reacting the resultant 2-pyridylacetamide derivative of formula III (including novel compounds) with equimolar amount of a compound of formula IV in an inert solvent or in the absence of solvent at 100-120 deg.C for 2-10hr and treating and purifying the reaction product by conventional method.
The invention discloses a calcium alginate-chitosan sustained-release microsphere carrying growth hormone. The sustained-release microsphere comprises the principal components including the growth hormone, the calcium alginate and the chitosan. The sustained-release microsphere can be used for preparing the drugs for fracture healing. The sustained-release microsphere has good sphericity and narrow particle size distribution range and can further sustain the release and absorption of the drugs. The microsphere features simple and efficient shaping process and mild shaping conditions. The growth hormone has high entrapment rate and activity, and organic solvents are unnecessary, etc.
A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. The starting dose of PT199 to be evaluated in the dose escalation study is 10 mg/kg weekly (QW). The dose level of PD-1 inhibitor, Tislelizumab in all provisional dose levels will be 200 mg once every 3 weeks (Q3W).
PURPOSE:To exactly measure the HBs antigen in a specimen by fixing an anti-HBs antibody via a crosslinking agent to the surface of liposome and sealing a hydrophilic labeling material in the liposome. CONSTITUTION:The liposome consists of phospholipid and cholesterol as its main constituting components. The labeling material to be sealed into the liposome is the material which is hydrophilic and can be quantitatively determined when eluted to the outside of the liposome. The reagent for measuring the HBs antigen and complement are added into the specimen to induce the conjugation reaction of the antigen-antibody and the complement in order to measure the HBs antigen in the specimen by using this reagent. The labeling material is then released from the inside of the liposome in proportion to the reaction amt. The quantitative determination is then executed by the analysis method meeting this labeling material and the quantity of the antigen in the sample is measured by, for example, a previously measured calibration curve.
Obesity and sedentarism are associated with increased liver and pancreatic fat content (LFC and PFC, respectively) as well as impaired organ metabolism. Exercise training is known to decrease organ ectopic fat but its effects on organ metabolism are unclear. Genetic background affects susceptibility to obesity and the response to training. We studied the effects of regular exercise training on LFC, PFC, and metabolism in monozygotic twin pairs discordant for BMI. We recruited 12 BMI-discordant monozygotic twin pairs (age 40.4, SD 4.5 years; BMI 32.9, SD 7.6, 8 female pairs). Ten pairs completed six months of training intervention. We measured hepatic insulin-stimulated glucose uptake using [18F]FDG-PET and fat content using magnetic resonance spectroscopy before and after the intervention. At baseline LFC, PFC, gamma-glutamyl transferase (GT), and hepatic glucose uptake were significantly higher in the heavier twins compared to the leaner co-twins (p = 0.018, p = 0.02 and p = 0.01, respectively). Response to training in liver glucose uptake and GT differed between the twins (Time*group p = 0.04 and p = 0.004, respectively). Liver glucose uptake tended to decrease, and GT decreased only in the heavier twins (p = 0.032). In BMI-discordant twins, heavier twins showed higher LFC and PFC, which may underlie the observed increase in liver glucose uptake and GT. These alterations were mitigated by exercise. The small number of participants makes the results preliminary, and future research with a larger pool of participants is warranted.
<P>PROBLEM TO BE SOLVED: To provide a new signal transduction protein participating in signal transduction of proinflammatory cytokine (interleukin-1) IL-1: a method for screening a compound inhibiting the signal transduction of IL-1 using the protein: and an IL-1 signal transduction inhibitor containing a compound separable by the screening as an active component.  <P>SOLUTION: There is provided a new signal transduction factor TAB2 acting as an adaptor molecule of TRAF6 and TAK1 and mediating activation of TAK1 in signal transduction of IL-1. TAB2 induces activation of NF-κB and JNK by IL-1. The signal transduction of TAB2 by IL-1 is inhibited by inhibiting the signal transduction of TAB2 by a dominant negative mutant of TAB2. There is further provided a medicine inhibiting signal transduction of TAB2 and having anti-inflammatory action.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Stabilization of colloidals systems through the formation of ionic lipid-polisaccharide complexes. There is disclosed a process for the preparation of colloidal systems which includes the incorporation of a water soluble and positively charged amino polysaccharide and a negatively charged phospholipid. The colloidal systems (which comprise polymer nanoparticles, nanocapsules and nano-emulsions) are stabilized through the formation of a ionic complex, at the interface, comprised of the aminopolysaccharide and the phospholipid. The colloidal systems are characterized in that they have a particle size lower than 1  mu m, an electric positive charge and an exeptional stability during storage. They are lyophilizable so that they can be dry stored and redispersed subsequently while maintaining the original characteristics of the system. They are useful as pharmaceutical forms for the oral, transdermic, topical, ocular, nasal and vaginal administration of medicaments. They are also useful as forms for cosmetic use.
Safety and efficacy of METRONIDAZOLE CREAM were evaluated in two randomized vehicle-controlled clinical studies for the treatment of rosacea, which excluded patients who had nodules, moderate or severe rhinophyma, dense telangiectases, plaque-like facial edema or ocular involvement and those who had a history of not responding to metronidazole therapy for rosacea. Of the patients included in the efficacy database (n=416), there were 142 men and 274 women. Endpoint efficacy data comparisons for patients treated with daily METRONIDAZOLE CREAM or vehicle applications are listed below.

*Statistically significant differences between METRONIDAZOLE CREAM and vehicle groups with p≤0.05. Erythema scores: 0=none, 1=mild, 2=moderate and 3=severe.

###  Safety Studies: 

Studies of contact sensitization (n=258), phototoxicity (n=21), and photocontact sensitization (n=29) of METRONIDAZOLE CREAM were conducted. No evidence of sensitization or phototoxicity was seen in these studies.
The invention discloses a hospital medical record large text intelligent variable software technique method, which belongs to the technical field of automatic management system generation. In many years, software development has a research and development technique in a fixed format, and a customer can not create or change system scheme application during use but can only accept the fixed format, data and algorithm application. Many management requirement statistical data can not realize changed application, the management scheme needs to be changed and updated for the changed application, repeated research and development result in work trouble, human waste and large input loss. The management work method needs to be changed randomly according to requirements, the hospital medical record large text intelligent variable software technique can meet various changed application requirements of the medical record large text management work only, thereby improving the management level, improving the working efficiency and saving the working time. Due to the hospital medical record large text intelligent variable software technique, the customer himself or herself adopts the large text change operation application, and changed application in aspects of a large text format technique, a data technique, a format data combination technique, a window graph technique and a data searching and positioning technique can be realized. The operation is convenient, quick and high in efficiency. The technique of the invention is a comprehensive application technique method for the intelligent management system automatic generation system, and all ideas, the design method and the software technique are originally created.
NEW MATERIAL: 3-Aminopropanesulfonic acid derivative represented by the formula (M is Ca or Mg). EXAMPLE: Calcium N-acetyl-3-aminopropanesulfonate. USE: A membrane stabilizer. Its Ca salt can be utilized as a neurotropic agent, while its MG salt, as a vasotropic agent. PREPARATION: A base of the formula: M(OH)2 and 3-aminopropanesulfonic acid is dissolved in water, when necessary, acetic acid is admixed. Then, acetic anhydride is added to the resultant solution and their reaction is continued for more than 1 hour at (30-40 deg.C to give the compound of the formula.
<P>PROBLEM TO BE SOLVED: To accurately associate medical images stored in portable storage media with patients.  <P>SOLUTION: A portable medium 50 created in a hospital A stores medical image data with a patient ID attached and patient profile information including the patient ID. A patient reception apparatus 10b in a hospital B reads the patient profile information from the portable medium 50, generates ID change command information for changing the patient ID to a patient ID specific to the hospital B, and sends the ID change command information as well as the patient profile information to an image server 30b. The image server 30b receives the patient profile information and ID change command information sent from the patient reception apparatus 10b. The image server 30b then reads the medical image data from the portable medium 50, changes the patient ID attached to the medical image data to the patient ID specific to the hospital B according to the ID change command information received from the patient reception apparatus 10b, and stores the changed medical image data.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Blood-brain barrier (BBB) prevention is greater than 500 daltonian molecules and is transported to brain from blood. The receptor-mediated dysuria due to the pressure of the fetus gulps down (RMT) and promotes to transport through BBB with the specific molecular that forms the receptors bind on the brain endothelial cell of BBB. Identify by RMT and moved type-1 insulin like growth factor acceptor (IGF 1R) binding antibodies or its fragment through BBB. Described antibody or fragment are used to delivering goods molecule through BBB, and wherein said cargo molecule can be that therapeutic agent maybe can detect reagent. Described antibody is camel V H H, by preparing with 933 amino acid whose IGF 1R polypeptide immune yammas. Also produce camel V H The humanization form of H.
BACKGROUND: Thyroid hormones act on the cardiovascular system directly by modulating its function and indirectly by transcriptional regulation of gene expression in the heart and the vasculature. Studies have shown associations between overt and subclinical thyroid disorders and cardiovascular outcomes. The aim of this study was to perform a systematic review and meta-analysis to assess the potential relationships between subclinical hyper- and hypothyroidism and risk of atrial fibrillation (AF), and post-operative AF.
METHODS: MEDLINE and Scopus databases were searched from inception to 18th February 2023 for randomised controlled trials, case-control studies, and cohort studies which assessed the relationship between subclinical thyroid dysfunction and incident AF events. Risk of bias and the quality of evidence were assessed using the RoBANS tool and GRADE approach, respectively. Meta-analysis was conducted in Review Manager 5.4 using the Mantel-Haenszel statistical method and a random-effects model. Data are presented as risk ratios with 95% confidence intervals. Statistical heterogeneity amongst studies was assessed by the chi-squared (χ2) test and I2 statistic. p≤0.05 were considered significant.
RESULTS: A total of 6467 records were identified, of which 10 cohort studies met the inclusion criteria. Both subclinical hyperthyroidism and subclinical hypothyroidism were associated with an increased risk of incident AF (risk ratio (RR), 1.99; 95% confidence interval (CI), 1.43-2.77; n = 5 studies; p<0.0001 and RR, 1.19; CI, 1.03-1.39; n = 7 studies; p = 0.02, respectively). Subgroup analysis for post-operative AF revealed marked heterogeneity between studies (I2 = 84%) and association with subclinical hypothyroidism was not significant (RR, 1.41; CI, 0.89-2.22; n = 3 studies; p = 0.15).
CONCLUSIONS: The current evidence suggests that both subclinical hyperthyroidism and subclinical hypothyroidism are associated with increased risk of incident AF. Further investigation is required to determine potential causal links that would guide future clinical practice.
Skin without intervention and irradiation. Skin biopsy will be taken as a control. Skin tissue will be stained to see sunburn cells and assesses the expression of MMP-9, Thymine Dimer, and p-53 by immunohistochemistry.
Aryl-substituted and aryl and (3-oxo-1-propenyl)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities.  The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.
The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
Nerve compression, disc herniation, and fracture-related factors may play a role in the etiology of chronic neck pain, or the pain may not be associated with a specific cause. In the cervical region, muscles, fascia, disc, nerve root and facet joints are the structures that carry pain. Problems related to these structures can also cause pain in the cervical region and shoulder, arm, interscapular region and craniocervical structures. The stomatognathic system is the integrity of the structures that perform the functions of chewing, swallowing and speaking. This system in the head and neck region; It consists of bones, muscles, joints, ligaments, teeth, supporting dental tissues, glands, tongue, mouth and surrounding tissues, and neuromuscular system. The relationship between the stomatognathic and craniocervical systems is demonstrated by the interaction between masticatory and cervical muscles. Wiesinger et al. examined the relationship between spinal pain and temporamandibular joint disorders in a large sample and stated that both conditions may share common risk factors or affect each other. The coexistence of cervical spine and temporomandibular joint pathologies (TMJ) is explained by the neuroanatomical convergence of nociceptive neurons receiving trigeminal and neck sensory inputs. Studies have shown that neck disability may be accompanied by jaw joint disability, masseter myofascial pain, and regional muscle tenderness. Olivio et al. He reported that the treatment of individuals with TMJ pathology should also focus on the neck region, because improvement of one may affect the other. Based on this idea, Calixtre et al. reported that they achieved positive improvements in pain and jaw functions in their study investigating the effects of cervical region mobilization and exercises on individuals with TMJ.

In the treatment of chronic neck pain, it has been shown that craniocervical flexion exercise, cervical stabilization and endurance exercises, aerobic exercises, proprioceptive exercises and patient education, especially strengthening exercises for deep and superficial flexor muscles, reduce pain and improve quality of life by increasing muscle strength and functions. In the literature, the number of studies investigating the effectiveness of an exercise program for the jaw joint in individuals with chronic neck pain is quite limited. In this context, our aim is to investigate the effects of Rocabado exercises, one of the jaw joint exercises, on pain, pain threshold/tolerance, range of motion, proprioception, disability, quality of life, muscle strength, muscle endurance, sleep quality and posture in individuals with chronic neck pain.
Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
Design \& procedures - This is an observational study in the real world clinical setting to evaluate immunosuppressive treatment (IS) of myasthenia gravis (MG). Patients with acquired autoimmune MG ≥ 18 years of age who are not on IS agents, and have not been on corticosteroids for at least 30 days will be enrolled at 20 sites in the US and Canada. These patients will be treated according to the physician's judgment and patient preferences as in routine clinical practice. Patients will be followed prospectively, with the frequency of clinical visits and laboratory monitoring determined by the treating physician, which may differ among patients. Standard outcome measures measuring efficacy and adverse effects that are used in clinical practice will be collected, with emphasis on patient reported outcomes. Informed consent will be obtained using an approved consent form. Patient identifiable / clinical information from the medical record, including the study outcome measures will be uploaded to a centralized REDCap database. The investigators plan to recruit 220 patients, adjusting for a 10% drop out rate, with a final sample of 200 patients for analysis.
This study is an observer-blind, prospective randomized, controlled study to evaluate efficacy and safety of fixed dose combination of eperisone hydrochloride 50 mg and diclofenac sodium 50 mg three times daily with plain eperisone hydrochloride 50 mg three times daily in patients with musculoskeletal spasm associated with low back pain. A total of 240 adult patients of either sex, 120 patients in each arm, who fulfill the inclusion and exclusion criteria will be included in this study. The patients will be evaluated at Days 3, 7 and 10 of the study visit for efficacy and safety. The efficacy evaluation includes objective parameters like Finger-to-Floor distance, Lasegue's sign, tenderness of par vertebral muscles, lumbar and dorsal hypermyotonia, leg tendon reflexes, need for rescue medication and subjective parameters like improvement in lumbar cinesalgia, pain in lower extremities, sensory disturbances of lower limb, and Global Assessment of Response to Therapy (PGART). Patients will be evaluated for safety on the clinical adverse events reported during the study period, sedation on drowsy alert scale and Global Assessment of Tolerability to Therapy (PGATT). The patients will also be evaluated for laboratory safety as assessed by measuring laboratory parameters for hemogram, renal and hepatic parameters.
Sepsis is characterized as life-threatening organ dysfunction caused by a dysregulated host response to an infection. Despite numerous clinical trials that addressed this syndrome, there is still no causative treatment available to dampen its severity. Curtailing the infection at an early stage with anti-infectives is the only effective treatment regime besides intensive care. In search for additional treatment options, we recently discovered the inhibition of the sphingosine 1-phosphate (S1P) lyase and subsequent activation of the S1P receptor type 3 (S1PR3) in pre-conditioning experiments as promising targets for sepsis prevention. Here, we demonstrate that treatment of septic mice with the direct S1P lyase inhibitor C31 or the S1PR3 agonist CYM5541 in the advanced phase of sepsis resulted in a significantly increased survival rate. A single dose of each compound led to a rapid decline of sepsis severity in treated mice and coincided with decreased cytokine release and increased lung barrier function with unaltered bacterial load. The survival benefit of both compounds was completely lost in S1PR3 deficient mice. Treatment of the murine macrophage cell line J774.1 with either C31 or CYM5541 resulted in decreased protein kinase B (Akt) and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) phosphorylation without alteration of the mitogen-activated protein kinase (MAPK) p38 and p44/42 phosphorylation. Thus, activation of S1PR3 in the acute phase of sepsis by direct agonism or S1P lyase inhibition dampened Akt and JNK phosphorylation, resulting in decreased cytokine release, improved lung barrier stability, rapid decline of sepsis severity and better survival in mice.